Table 7.

Association of clinicopathological characteristics (including XBP1 and NAT1 expression) with average survival of GBC, SC/ASC, and AC patients.

Clinicopathological characteristics	GBC			SC/ASC			AC
	Sample (n)	AS (month)	P	Sample (n)	AS (month)	P	Sample (n)	AS (month)	P
Differentiation
Well	70	15.84 (5-24)	0.000	19	13.68 (5-24)	0.000	51	16.69 (5-24)	0.000
Moderately	87	11.63 (2-24)		33	11.58 (4-24)		54	12.33 (2-24)
Poorly	58	6.38 (1-24)		17	6.12 (2-14)		41	6.49 (1-24)
Tumor size
≤3 cm	129	12.43 (1-24)	0.026	30	14.57 (6-24)	0.000	90	14.60 (1-24)	0.000
>3 cm	86	10.31 (1-24)		39	7.44 (2-24)		56	8.38 (1-24)
Gallstones
No	109	11.07 (2-24)	0.371	31	8.26 (3-18)	0.008	78	12.19 (2-24)	0.980
Yes	106	12.11 (1-24)		38	12.90 (2-24)		68	12.24 (1-24)
TNM stage
I + II	106	16.44 (3-24)	0.000	29	16.31 (3-24)	0.000	77	16.99 (3-24)	0.000
III + IV	109	6.86 (1-14)		40	6.83 (2-14)		69	6.88 (1-24)
Lymph node metastasis
No	107	15.92 (2-24)	0.000	27	16.04 (3-24)	0.000	80	16.35 (2-24)	0.000
Yes	108	7.30 (1-24)		42	7.45 (2-15)		66	7.20 (1-24)
Invasion
No	96	17.48 (3-24)	0.000	24	17.25 (3-24)	0.000	72	18.08 (4-24)	0.000
Yes	119	6.83 (1-24)		45	7.38 (2-20)		74	6.50 (1-14)
Surgery
Radical	102	17.23 (5-24)	0.000	27	16.93 (5-24)	0.000	75	17.84 (6-24)	0.000
Palliative	78	7.03 (1-14)		28	7.32 (2-12)		50	6.86 (1-14)
Biopsy	35	5.31 (1-9)		14	6.00 (4-8)		21	4.86 (1-9)
XBP1
–	92	15.58 (4-24)	0.000	25	14.08 (4-24)	0.000	67	16.13 (4-24)	0.000
+	123	8.60 (1-24)		44	8.09 (2-24)		79	8.89 (1-24)
NAT1
–	122	8.48 (1-24)	0.000	42	7.64 (2-24)	0.001	80	8.93 (1-24)	0.000
+	93	15.66 (2-24)		27	14.33 (3-24)		66	16.20 (2-24)
XBP1 and NAT1
XBP1(–) and NAT1(–)	36	12.00 (4-24)	0.000	10	10.07 (4-24)	0.000	26	12.50 (4-24)	0.000
XBP1(–) and NAT1(+)	56	17.86 (4-24)		15	16.33 (7-24)		41	18.44 (4-24)
XBP1(+) and NAT1(–)	86	7.01 (1-24)		32	6.67 (2-14)		54	7.20 (1-24)
XBP1(+) and NAT1(+)	37	12.30 (2-24)		12	11.83 (3-24)		25	12.52 (2-24)

–, negative expression; +, positive expression; AS, average survival.